Look through the key statistics analysis before diving in deeper into our report:
| Parameter | Current result | Assessment |
|---|---|---|
| Meta title | Allergic Asthma and CIU Treatment | XOLAIR® (Omalizumab) | As meta title is a ranking factor, it's quite important to stick to search engine recommended length of aroun 50-60 characters. This website's meta title is 56 characters long. |
| Description | XOLAIR (omalizumab) for subcutaneous use is a prescription treatment for moderate to severe persistent allergic asthma and chronic idiopathic urticaria (CIU) in appropriate patients. What is XOLAIR? XOLAIR® (omalizumab) for subcutaneous use is an injectable prescription medicine used to treat patients 6 years of age and older with moderate to severe persistent asthma whose asthma symptoms are not controlled by asthma medicines called inhaled corticosteroids. A skin or blood test is performed to see if you have allergies to year-round allergens. XOLAIR is not used to treat other allergic conditions, acute bronchospasm or status asthmaticus. IMPORTANT SAFETY INFORMATION What is the most important information I should know about XOLAIR? Severe allergic reaction. A severe allergic reaction called anaphylaxis can happen when you receive XOLAIR. The reaction can occur after the first dose, or after many doses. It may also occur right after a XOLAIR injection or days later. Anaphylaxis is a life-threatening condition and can lead to death. Go to the nearest emergency room right away if you have any of these symptoms of an allergic reaction: wheezing, shortness of breath, cough, chest tightness, or trouble breathing, low blood pressure, dizziness, fainting, rapid or weak heartbeat, anxiety, or feeling of "impending doom," flushing, itching, hives, or feeling warm, swelling of the throat or tongue, throat tightness, hoarse voice, or trouble swallowing. Your healthcare provider will monitor you closely for symptoms of an allergic reaction while you are receiving XOLAIR and for a period of time after your injection. Your healthcare provider should talk to you about getting medical treatment if you have symptoms of an allergic reaction after leaving the healthcare provider's office or treatment center. Do not receive XOLAIR if you are allergic to omalizumab or any of the ingredients in XOLAIR. Before receiving XOLAIR, tell your healthcare provider about all of your medical conditions, including if you: have any other allergies (such as food allergy or seasonal allergies), have sudden breathing problems (bronchospasm), have ever had a severe allergic reaction called anaphylaxis, have or have had a parasitic infection, have or have had cancer, are pregnant or plan to become pregnant, are breastfeeding or plan to breastfeed. It is not known if XOLAIR may harm your unborn baby. It is not known if XOLAIR passes into your breast milk. Talk with your healthcare provider about the best way to feed your baby while you receive XOLAIR. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements. How should I receive XOLAIR? XOLAIR should be given by your healthcare provider, in a healthcare setting. XOLAIR is given in 1 or more injections under the skin (subcutaneous), 1 time every 2 or 4 weeks. In asthma patients, a blood test for a substance called IgE must be performed prior to starting XOLAIR to determine the appropriate dose and dosing frequency. Do not decrease or stop taking any of your other asthma medicine unless your healthcare providers tell you to. You may not see improvement in your symptoms right away after XOLAIR treatment. What are the possible side effects of XOLAIR? XOLAIR may cause serious side effects, including: See, "What is the most important information I should know about XOLAIR" regarding the risk of anaphylaxis. Cancer. Cases of cancer were observed in some people who received XOLAIR. Inflammation of your blood vessels. Rarely, this can happen in people with asthma who receive XOLAIR. This usually, but not always, happens in people who also take a steroid medicine by mouth that is being stopped or the dose is being lowered. It is not known whether this is caused by XOLAIR. Tell your healthcare provider right away if you have rash; chest pain; shortness of breath; or a feeling of pins and needles or numbness of your arms or legs. Fever, muscle aches, and rash. Some people who take XOLAIR get these symptoms 1 to 5 days after receiving a XOLAIR injection. If you have any of these symptoms, tell your healthcare provider. Parasitic infection. Some people who are at a high risk for parasite (worm) infections, get a parasite infection after receiving XOLAIR. Your healthcare provider can test your stool to check if you have a parasite infection. Heart and circulation problems. Some people who receive XOLAIR have had chest pain, heart attack, blood clots in the lungs or legs, or temporary symptoms of weakness on one side of the body, slurred speech, or altered vision. It is not known whether this is caused by XOLAIR. The most common side effects of XOLAIR: In adults and children 12 years of age and older with asthma: pain especially in your arms and legs, dizziness, feeling tired, skin rash, bone fractures, and pain or discomfort of your ears. In children 6 to less than 12 years of age with asthma: common cold symptoms, headache, fever, sore throat, pain or discomfort of your ear, abdominal pain, nausea, vomiting and nose bleeds. These are not all the possible side effects of XOLAIR. Call your doctor for medical advice about side effects. You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555 or Novartis Pharmaceuticals Corporation at (888) 669-6682. Please see full Prescribing Information, including Medication Guide for additional Important Safety Information. What is XOLAIR? XOLAIR® (omalizumab) for subcutaneous use is an injectable prescription medicine used to treat adults and children 12 years of age and older with chronic idiopathic urticaria (CIU; chronic hives without a known cause) who continue to have hives that are not controlled by H1 antihistamine treatment. XOLAIR is not used to treat other forms of urticaria. IMPORTANT SAFETY INFORMATION What is the most important information I should know about XOLAIR? Severe allergic reaction. A severe allergic reaction called anaphylaxis can happen when you receive XOLAIR. The reaction can occur after the first dose, or after many doses. It may also occur right after a XOLAIR injection or days later. Anaphylaxis is a life-threatening condition and can lead to death. Go to the nearest emergency room right away if you have any of these symptoms of an allergic reaction: wheezing, shortness of breath, cough, chest tightness, or trouble breathing, low blood pressure, dizziness, fainting, rapid or weak heartbeat, anxiety, or feeling of "impending doom," flushing, itching, hives, or feeling warm, swelling of the throat or tongue, throat tightness, hoarse voice, or trouble swallowing. Your healthcare provider will monitor you closely for symptoms of an allergic reaction while you are receiving XOLAIR and for a period of time after your injection. Your healthcare provider should talk to you about getting medical treatment if you have symptoms of an allergic reaction after leaving the healthcare provider's office or treatment center. Do not receive XOLAIR if you are allergic to omalizumab or any of the ingredients in XOLAIR. Before receiving XOLAIR, tell your healthcare provider about all of your medical conditions, including if you: have ever had a severe allergic reaction called anaphylaxis, have or have had a parasitic infection, have or have had cancer, are pregnant or plan to become pregnant, are breastfeeding or plan to breastfeed. It is not known if XOLAIR may harm your unborn baby. It is not known if XOLAIR passes into your breast milk. Talk with your healthcare provider about the best way to feed your baby while you receive XOLAIR. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements. How should I receive XOLAIR? XOLAIR should be given by your healthcare provider, in a healthcare setting. XOLAIR is given in 1 or more injections under the skin (subcutaneous), 1 time every 4 weeks. In patients with chronic hives, a blood test is not necessary to determine the dose or dosing frequency. Do not decrease or stop taking any of your other hive medicine unless your healthcare providers tell you to. You may not see improvement in your symptoms right away after XOLAIR treatment. What are the possible side effects of XOLAIR? XOLAIR may cause serious side effects, including: See, "What is the most important information I should know about XOLAIR" regarding the risk of anaphylaxis. Cancer. Cases of cancer were observed in some people who received XOLAIR. Fever, muscle aches, and rash. Some people who take XOLAIR get these symptoms 1 to 5 days after receiving a XOLAIR injection. If you have any of these symptoms, tell your healthcare provider. Parasitic infection. Some people who are at a high risk for parasite (worm) infections, get a parasite infection after receiving XOLAIR. Your healthcare provider can test your stool to check if you have a parasite infection. Heart and circulation problems. Some people who receive XOLAIR have had chest pain, heart attack, blood clots in the lungs or legs, or temporary symptoms of weakness on one side of the body, slurred speech, or altered vision. It is not known whether this is caused by XOLAIR. The most common side effects of XOLAIR: In people with chronic idiopathic urticaria: nausea, headaches, swelling of the inside of your nose, throat or sinuses, cough, joint pain, and upper respiratory tract infection. These are not all the possible side effects of XOLAIR. Call your doctor for medical advice about side effects. You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555 or Novartis Pharmaceuticals Corporation at (888) 669-6682. Please see full Prescribing Information, including Medication Guide for additional Important Safety Information. | This meta description is 10005 characters in length. Google suggests up to 320 characters at the very most to make sure the whole meta description is visible in search results page. |
| <meta> keywords | xolair, xolair injection, omalizumab, allergic asthma, allergic asthma treatment, allergy symptoms, year-round allergens, patient support program, severe asthma, ciu, chronic idiopathic urticaria, chronic hives | Strangely enough, meta keywords still seem to be used. We would not go down that road unless very carefully - meta keywords have not been known as a positive ranking factor for a while now. |
| Site speed | Around 2.8613 seconds | Website ranking and usability can be greatly improved by reducing the time it takes to load it. |
| Links on homepage | Around 29 links | This is a well-judged amount of links for a homepage. |
| HTML size | 39.4KB | Ah. Well. We were hoping for better results... We would urge the website owners to improve load speed as soon as possible. |
| Website host server overview | Server status: online. Server IP address for this website is 52.52.237.169. | We apologize, but for some reason we were unable to gather enough data to provide a detailed insight at this time. |
If the basic information we presented you with above is not enough, get ready to dive in much deeper!
Servers are physical storage devices that contain all the files and databases associated with a specific website, sometimes more than one. At times, a server makes up several virtual devices - separate servers used for shared hosting (tends to be cheaper). Entering website address into the address bar of your browser starts the request process during which your browser contacts the server and asks for specific files and database entries in order to display the requested website.
What follows is certainly very geeky, but informative for the knowing. Dig in:
| Header detail |
|---|
HTTP/1.1 200 OK Accept-Ranges: bytes Content-Type: text/html; charset=UTF-8 Date: Thu, 12 Oct 2017 10:59:29 GMT ETag: "9c69-55b4e7be9f095" Last-Modified: Thu, 12 Oct 2017 00:18:48 GMT Server: Apache ServerID: web01 Content-Length: 40041 Connection: Close |
Now that you are hopefully done with asthmamatters.com, we invite you to read more of our in-depth reports. Try entering a new domain address in the search form at the top of this page, or on the homepage. Alternatively, refer to this list for more website overviews:
We have found so many alternative TLD extensions for asthmamatters.com. Here is the full list with 580 entries:
The following list of most frequent domain address mistypes associated with asthmamatters.com contains at least 1275 entries: